• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RedChip CEO Dave Gentry Invited to Join Forbes Business Council

    1/25/23 8:00:00 AM ET
    $AREC
    $BIVI
    $GNS
    $RVPH
    Coal Mining
    Energy
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AREC alert in real time by email

    ORLANDO, FL / ACCESSWIRE / January 25, 2023 / RedChip Companies is pleased to announce its CEO, Dave Gentry, was recently welcomed as a member of the Forbes Business Council.

    The Forbes Business Council committee invited Gentry to join the elite group of business leaders in recognition of his passion for helping entrepreneurs achieve success. The invitation-only community is made up of successful business owners and executives who have been chosen based on their accomplishments and experience.

    As a member, Gentry will be able to leverage the Forbes Business Council's collective resources to help foster growth in the RedChip Companies community. He will also be able to participate in exclusive events, such as invite-only webinars and podcasts, publish expert insights as a contributing writer on the Forbes platform, access a private community of members, and more.

    Gentry commented, "I look forward to sharing insights gained from my decades of experience working with executives in the small-cap markets. I believe this is a great opportunity to enhance my contributions to the entrepreneurial spirit that drives business innovations globally, while also gaining valuable new insights from industry veterans."

    Gentry is the author of Small Stocks, Big Money, a Wiley-published book of interviews with the world's most successful small-cap investors. He has been a consultant to more than 1,000 public companies and assisted dozens of public companies in the up-listing and capital-raising process. In 2012 he founded The RedChip Money Report™, a weekly cable TV financial news show broadcast in 177 million homes. He has appeared on CNBC and Fox Business News and is widely known as a thought leader in the small-cap space.

    Gentry has been a presenter at the New York Society of Security Analysts, Deal Flow Media conferences, and other small-cap conferences, and he has rung the NASDAQ bell on three occasions. In 2011, he was honored by Inc. Magazine as CEO of one of the fastest-growing private companies in America. In 1996, he won the Republican nomination in the 5th District of Florida for the United States House of Representatives. In 1994 he co-founded the First Amendment Coalition, an independent, nonprofit, collegiate-based student organization, and received national and international attention for his work defending free speech on college campuses. Gentry's activism led to his book 100+ Cases of Campus Censorship, published by David Horowitz's Second Thoughts Books. Gentry earned his Master of Education from the University of Florida in 1993.

    RedChip currently represents more than 70 clients, including some of the best emerging growth companies in the small-cap space, such as Genius Group (NYSE:GNS), Reviva Pharmaceuticals (NASDAQ:RVPH), Zomedica (NYSE:ZOM), BioVie (NASDAQ:BIVI), and American Resources Corporation (NASDAQ:AREC).

    About Forbes Business Council

    The Forbes Business Council is an exclusive platform that brings together successful business owners and executives from all over the world. Members are handpicked by the Forbes Business Council committee based on their accomplishments, experience, and commitment to helping entrepreneurs reach their goals.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Matt Sheldon
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    matt@redchip.com

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/736680/RedChip-CEO-Dave-Gentry-Invited-to-Join-Forbes-Business-Council

    Get the next $AREC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AREC
    $BIVI
    $GNS
    $RVPH

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    3/5/2026Buy → Hold
    D. Boral Capital
    American Resources Corporation
    $AREC
    11/26/2025$7.00Buy
    Maxim Group
    American Resources Corporation
    $AREC
    10/20/2025Outperform
    William Blair
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    American Resources Corporation
    $AREC
    9/15/2025$6.00Buy
    D. Boral Capital
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/20/2023$12.00Buy
    ROTH MKM
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    6/8/2023$17.00Speculative Buy
    The Benchmark Company
    Zomedica Corp.
    $ZOM
    1/6/2023$6.00Buy
    Dawson James
    More analyst ratings

    $AREC
    $BIVI
    $GNS
    $RVPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

    6/23/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Industrial Specialties

    Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th

    CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD., Founder, President and CEO, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 24th, 2026. DATE: June 24th TIME: 1:30 PM ET REGISTER HERE Reviva Management is available for 1x1 meetings: June 26 and June 30. To schedule 1x1 Meetings, please click here The event will be conducted

    6/23/26 8:00:00 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genius Group Buys Back 6,037,851 Company Shares

    32.6 million shares removed from Company’s issued share capital in last 8 days, equivalent to 27% of the Company’s public float. SINGAPORE, June 22, 2026 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group", "GNS" or the "Company"), a leading AI-powered education group, today announced that it has bought back 6,037,851 Class A Ordinary Shares in a privately negotiated off-market transaction with a non-affiliated private holder, which together with the 6.6 million shares buyback announced on June 15, 2026 represents 96% of the 13.2 million share buyback authorised by the Company’s Board of Directors on June 7, 2026. The repurchase was executed in a privately negotiated tran

    6/22/26 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AREC
    $BIVI
    $GNS
    $RVPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 12,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/20/25 12:33:35 PM ET
    $AREC
    Coal Mining
    Energy

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Golden Properties Ltd. decreased direct ownership by 7% to 13,389,960 units (SEC Form 4)

    4 - American Resources Corp (0001590715) (Issuer)

    8/1/25 1:26:00 PM ET
    $AREC
    Coal Mining
    Energy

    $AREC
    $BIVI
    $GNS
    $RVPH
    SEC Filings

    View All

    SEC Form 6-K filed by Genius Group Limited

    6-K - Genius Group Ltd (0001847806) (Filer)

    6/22/26 8:42:57 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form S-3 filed by BioVie Inc.

    S-3 - BIOVIE INC. (0001580149) (Filer)

    6/18/26 5:21:26 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Genius Group Limited

    6-K - Genius Group Ltd (0001847806) (Filer)

    6/17/26 9:15:08 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AREC
    $BIVI
    $GNS
    $RVPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AREC
    $BIVI
    $GNS
    $RVPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SEC Form 4 filed by Prabhu Narayan

    4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

    3/20/26 5:00:47 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bhat Laxminarayan

    4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

    3/20/26 5:00:20 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Palumbo Joseph M

    4 - BIOVIE INC. (0001580149) (Issuer)

    1/9/26 5:03:29 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reviva Pharmaceuticals downgraded by D. Boral Capital

    D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold

    3/5/26 8:53:11 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on American Resources Corp. with a new price target

    Maxim Group initiated coverage of American Resources Corp. with a rating of Buy and set a new price target of $7.00

    11/26/25 7:50:43 AM ET
    $AREC
    Coal Mining
    Energy

    William Blair initiated coverage on American Resources Corp.

    William Blair initiated coverage of American Resources Corp. with a rating of Outperform

    10/20/25 8:43:21 AM ET
    $AREC
    Coal Mining
    Energy

    $AREC
    $BIVI
    $GNS
    $RVPH
    Leadership Updates

    Live Leadership Updates

    View All

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Genius Group Engages DLA Piper as Advisor on Australian Securities Exchange (ASX) Dual Listing.

    SINGAPORE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that it has appointed DLA Piper as advisor on the Company's application for a dual listing on Australian Securities Exchange (ASX). Following the Company's Board of Directors approval on August 8, 2025 to pursue a dual listing on an Asia Pacific exchange to enhance shareholder value and accessibility, the Company has been investigating potential stock exchanges, resulting in a shortlist of three exchanges in Australia (ASX), South Korea (KRX) and Hong Kong (HKEX). From the shortlist, the Company has selected t

    12/18/25 8:00:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Genius Group Announces New Analyst Report from Diamond Equity Research

    SINGAPORE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE:GNS) ("Genius Group", "GNS" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced the release of a new Analyst Update Report from Diamond Equity Research, an issuer sponsored equity research firm focused on small capitalization companies, covering Genius Group's common stock. Genius Group has worked with Diamond Equity Research to perform independent research that will create greater awareness and exposure in the investment community for the company's AI-powered education growth plans and Bitcoin Treasury strategy. Report Highlights Notable highlights from the report include: Broad

    11/24/25 8:30:00 AM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AREC
    $BIVI
    $GNS
    $RVPH
    Financials

    Live finance-specific insights

    View All

    BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

    -Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company's ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID. The Phase 2 study is fully funded by a grant from the U.S. Department of War (DoW, formerly the U.S. Department of Defense). An estimated 15 million U.S. adults reported having long COVID between 2022 and 2023, with 3.8 million experiencing significant lim

    5/26/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease

    CARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last patient evaluation visit has been completed for the Company's SUNRISE-PD Phase 2 trial evaluating its drug candidate bezisterim in early-stage Parkinson's disease. "With this last patient's treatment visit completed, our team will start the study closeout process, and the Company plans announce topline results in Q3," said Cuong Do, BioVie's President and CEO. "This trial was designed to assess bezisterim's magnitude of therapeutic impact on a s

    5/18/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

    CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how bezisterim's mechanism of action could potentially address the pathology and progression of neurodegenerative diseases, including Parkinson's disease. To register, click here. The event will provid

    4/27/26 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AREC
    $BIVI
    $GNS
    $RVPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Genius Group Limited

    SC 13G - Genius Group Ltd (0001847806) (Subject)

    11/14/24 5:32:28 PM ET
    $GNS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 5:16:56 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Reviva Pharmaceuticals Holdings Inc.

    SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)

    11/14/24 4:15:57 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care